
Arbutus Biopharma Corporation: stock overview
Price
$4.02
November 20, 2026Market cap $799M
What Ploutos Investor adds for Arbutus Biopharma
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Profit over the last twelve months is well above what the business itself earned, because it includes large gains outside the business, such as on investments or from selling a business. The P/E is lower than the business alone would give.
In short
Arbutus Biopharma had revenue of $181M over the last 12 months and net income of $220M, a net margin of 121.2%. Revenue grew by 15.3% a year on average over the last 5 years. At $4.02 the shares trade at a P/E of 3.6. It holds more cash than debt, by $337M. It pays no dividend.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 20, 2026.
Its SEC filings- Market cap
- $799M
- 199M shares
- P/E
- 3.6
- Revenue, 12 months
- $181M
- +15.3% a year over 5 years
- Net margin
- 121.2%
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
-11.9% a year over 2 years
Fiscal years in figures
ABUS's revenue, profit, cash flow and dividend with each year-end price, from 2009 to 2022, 14 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $626M
- $799M
- Enterprise value
- $461M
- P/E
- 3.6
- EV / EBIT
- 3.1
- EV / Revenue
- 2.5
- P/B 3-year median: 6.4
- 9.3
- FCF yield 3-year median: -10.4%
- 27.7%
- Earnings yield 3-year median: -11.6%
- 27.5%
Profitability
- Operating margin
- 81.1%
- Net margin 3-year median: -401.6%
- 121.2%
- ROIC
- 76.6%
- ROIC, 5-year average
- -46.3%
- ROE
- 144.9%
Growth
- Revenue, yearly change
- +128.2%
- EPS, yearly change
- –
- FCF, yearly change
- –
- Revenue, average a year
- +15.3%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $337M
- Total debt
- $328.0K
- Of which operating leases
- $328.0K
- Net cash
- $337M
- Net debt / EBITDA
- -2.3x
- Interest cover
- 2,299.4x
- Current ratio
- 1.40
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +2.1%
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- Arbutus Biopharma Corp
- CIK
- 1447028
- Exchange
- NASDAQ
- Industry (SIC)
- 2834 · Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 199M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with ABUS
- JNJJohnson & Johnson+0,00%Compare with ABUS
- ABBVAbbVie+0,00%Compare with ABUS
- UNHUnitedHealth+0,00%Compare with ABUS
- MRKMerck & Company+0,00%Compare with ABUS
- AMGNAmgen+0,00%Compare with ABUS
- TMOThermo Fisher Scientific+0,00%Compare with ABUS
- ABTAbbott Laboratories+0,00%Compare with ABUS
The full analysis
What do Arbutus Biopharma's filings show?
These are Arbutus Biopharma's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is ABUS's market cap?
Arbutus Biopharma Corporation's market cap is $799M, at a price of $4.02 on November 20, 2026 and 199M shares.
What is ABUS's P/E?
ABUS's P/E is 3.6, on earnings per share of $1.13 over the last 12 months.
How much revenue does ABUS have?
Arbutus Biopharma had revenue of $181M over the last 12 months. Over the last 5 years it changed by +15.3% a year on average.
Does ABUS pay a dividend?
No. Arbutus Biopharma paid no regular dividend over the last 12 months.
Where do the figures come from?
From Arbutus Biopharma Corporation's SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.